Opko Health Inc. (NYSE:OPK) – Investment analysts at Oppenheimer Holdings issued their Q3 2016 earnings estimates for shares of Opko Health in a research report issued to clients and investors on Sunday. Oppenheimer Holdings analyst M. Ho forecasts that the brokerage will post earnings of ($0.01) per share for the quarter. Oppenheimer Holdings has a “Hold” rating on the stock. Oppenheimer Holdings also issued estimates for Opko Health’s Q4 2016 earnings at ($0.02) EPS, FY2016 earnings at ($0.03) EPS, FY2017 earnings at $0.03 EPS, FY2018 earnings at $0.61 EPS, FY2019 earnings at $1.17 EPS and FY2020 earnings at $1.85 EPS.

Several other research firms have also weighed in on OPK. JPMorgan Chase & Co. set a $14.00 price objective on Opko Health and gave the company a “buy” rating in a research note on Tuesday, August 9th. Jefferies Group reiterated a “hold” rating on shares of Opko Health in a research note on Wednesday, August 17th. Zacks Investment Research upgraded Opko Health from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. Deutsche Bank AG lowered their price objective on Opko Health from $11.00 to $10.00 and set a “hold” rating on the stock in a research note on Thursday, June 16th. Finally, Standpoint Research upped their price objective on Opko Health from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, June 21st. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $13.20.

Earnings History and Estimates for Opko Health (NYSE:OPK)

Shares of Opko Health (NYSE:OPK) opened at 9.56 on Wednesday. Opko Health has a one year low of $7.12 and a one year high of $11.85. The stock has a market capitalization of $5.26 billion and a P/E ratio of 40.00. The company’s 50 day moving average price is $10.06 and its 200 day moving average price is $10.08.

Opko Health (NYSE:OPK) last announced its earnings results on Monday, August 8th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.05. The company had revenue of $357.10 million for the quarter, compared to analysts’ expectations of $324.11 million. The business’s quarterly revenue was up 742.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.09) earnings per share.

In other news, CEO Phillip Md Et Al Frost acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, August 2nd. The shares were purchased at an average cost of $9.88 per share, for a total transaction of $98,800.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $30,321,235.88. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. ProShare Advisors LLC bought a new position in Opko Health during the second quarter worth $100,000. Financial Architects Inc increased its position in Opko Health by 21.5% in the second quarter. Financial Architects Inc now owns 10,950 shares of the company’s stock worth $102,000 after buying an additional 1,940 shares during the period. First Citizens Bank & Trust Co. bought a new position in Opko Health during the second quarter worth $103,000. Williams Jones & Associates LLC increased its position in Opko Health by 352.0% in the second quarter. Williams Jones & Associates LLC now owns 11,300 shares of the company’s stock worth $106,000 after buying an additional 8,800 shares during the period. Finally, Nuveen Fund Advisors LLC bought a new position in Opko Health during the second quarter worth $131,000.

About Opko Health

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.